Brief communication: efficacy and safety of the dolutegravir/lamivudine dual therapy in antiretroviral treatment-experienced Chinese people living with HIV

AIDS Res Ther. 2024 Nov 27;21(1):86. doi: 10.1186/s12981-024-00680-x.

Abstract

This study aimed to evaluate the efficacy and safety of dolutegravir plus lamivudine (DTG/3TC) in antiretroviral treatment (ART)-experienced people living with HIV (PLWH). A total of 303 PLWH in Shanghai, China, who switched from triple ART to DTG/3TC between January 2019 and June 2022, with a minimum ART duration of 6 months, were retrospectively enrolled. More than 95% of PLWH maintained viral suppression with no significant changes in CD4 counts 12 months after switching. Patients transitioning from non-tenofovir (TDF)-based regimens demonstrated more pronounced improvements in lipid profiles, while those previously on TDF-based regimens showed greater enhancements in bone metabolism.

Keywords: Antiretroviral; Dolutegravir; HIV; Lamivudine.

MeSH terms

  • Adult
  • Anti-HIV Agents* / adverse effects
  • Anti-HIV Agents* / therapeutic use
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • China
  • Drug Therapy, Combination
  • East Asian People
  • Female
  • HIV Infections* / drug therapy
  • HIV Infections* / virology
  • HIV-1 / drug effects
  • Heterocyclic Compounds, 3-Ring* / administration & dosage
  • Heterocyclic Compounds, 3-Ring* / adverse effects
  • Heterocyclic Compounds, 3-Ring* / therapeutic use
  • Humans
  • Lamivudine* / therapeutic use
  • Male
  • Middle Aged
  • Oxazines* / therapeutic use
  • Piperazines* / therapeutic use
  • Pyridones* / therapeutic use
  • Retrospective Studies
  • Treatment Outcome
  • Viral Load / drug effects

Substances

  • Lamivudine
  • Pyridones
  • Heterocyclic Compounds, 3-Ring
  • Oxazines
  • dolutegravir
  • Piperazines
  • Anti-HIV Agents

Supplementary concepts

  • Chinese people